ERBB2 and invasive breast carcinoma: Six-hundred-and-thirty-nine (81.8%) meta-analytic estimates pertained to overall BrCa incidence or mortality (with 7 estimates being specific to BrCa ­related mortality), while 131 (16.8%) focused on BrCa molecular subtypes, i.e., estrogen (ER), progesterone (PR), HER2, luminal A and B, and triple-negative, and 11 (1.4%) specifically to the locoregional spread, i.e., in-situ, invasive, localised, non-localised.